<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Topiramate for essential tremor - Bruno, E - 2017 | Cochrane Library</title> <meta content="Topiramate for essential tremor - Bruno, E - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009683.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Topiramate for essential tremor - Bruno, E - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009683.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009683.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Topiramate for essential tremor" name="citation_title"/> <meta content="Elisa Bruno" name="citation_author"/> <meta content="University of Catania" name="citation_author_institution"/> <meta content="e.bruno@hotmail.it" name="citation_author_email"/> <meta content="Alessandra Nicoletti" name="citation_author"/> <meta content="University of Catania" name="citation_author_institution"/> <meta content="Graziella Quattrocchi" name="citation_author"/> <meta content="University of Catania" name="citation_author_institution"/> <meta content="Roberta Allegra" name="citation_author"/> <meta content="Policlinico Universitario G. Martino Messina" name="citation_author_institution"/> <meta content="Graziella Filippini" name="citation_author"/> <meta content="Fondazione IRCCS, Istituto Neurologico Carlo Besta" name="citation_author_institution"/> <meta content="Carlo Colosimo" name="citation_author"/> <meta content="Terni University Hospital" name="citation_author_institution"/> <meta content="Mario Zappia" name="citation_author"/> <meta content="University of Catania" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD009683.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/04/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009683.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009683.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009683.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Activities of Daily Living; Anticonvulsants [adverse effects, *therapeutic use]; Essential Tremor [*drug therapy]; Fructose [adverse effects, *analogs &amp; derivatives, therapeutic use]; Patient Dropouts [statistics &amp; numerical data]; Publication Bias; Randomized Controlled Trials as Topic; Topiramate" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009683.pub2&amp;doi=10.1002/14651858.CD009683.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009683.pub2&amp;doi=10.1002/14651858.CD009683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009683.pub2&amp;doi=10.1002/14651858.CD009683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009683.pub2&amp;doi=10.1002/14651858.CD009683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009683.pub2&amp;doi=10.1002/14651858.CD009683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009683.pub2&amp;doi=10.1002/14651858.CD009683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009683.pub2&amp;doi=10.1002/14651858.CD009683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009683.pub2&amp;doi=10.1002/14651858.CD009683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009683.pub2&amp;doi=10.1002/14651858.CD009683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009683.pub2&amp;doi=10.1002/14651858.CD009683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009683.pub2&amp;doi=10.1002/14651858.CD009683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009683.pub2&amp;doi=10.1002/14651858.CD009683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009683.pub2&amp;doi=10.1002/14651858.CD009683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009683.pub2&amp;doi=10.1002/14651858.CD009683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009683.pub2&amp;doi=10.1002/14651858.CD009683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009683.pub2&amp;doi=10.1002/14651858.CD009683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009683.pub2&amp;doi=10.1002/14651858.CD009683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009683.pub2&amp;doi=10.1002/14651858.CD009683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009683.pub2&amp;doi=10.1002/14651858.CD009683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009683.pub2&amp;doi=10.1002/14651858.CD009683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009683.pub2&amp;doi=10.1002/14651858.CD009683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009683.pub2&amp;doi=10.1002/14651858.CD009683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009683.pub2&amp;doi=10.1002/14651858.CD009683.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="1ljSZou6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009683\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009683\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009683\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009683\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","fr","pl","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009683.pub2",title:"Topiramate for essential tremor",firstPublishedDate:"Apr 14, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Movement Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009683.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009683.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009683.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009683.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009683.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009683.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009683.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009683.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009683.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009683.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4225 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009683.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/full#CD009683-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/full#CD009683-sec-0090"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/full#CD009683-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/full#CD009683-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/full#CD009683-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/full#CD009683-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/full#CD009683-sec-0058"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/full#CD009683-sec-0084"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/appendices#CD009683-sec-0095"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/table_n/CD009683StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/table_n/CD009683StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Topiramate for essential tremor</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/information#CD009683-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Elisa Bruno</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/information#CD009683-cr-0003">Alessandra Nicoletti</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/information#CD009683-cr-0004">Graziella Quattrocchi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/information#CD009683-cr-0005">Roberta Allegra</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/information#CD009683-cr-0006">Graziella Filippini</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/information#CD009683-cr-0007">Carlo Colosimo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009683.pub2/information#CD009683-cr-0008">Mario Zappia</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/information/en#CD009683-sec-0100">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 April 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009683.pub2">https://doi.org/10.1002/14651858.CD009683.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009683-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009683-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009683-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009683-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009683-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009683-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009683-abs-0001" lang="en"> <section id="CD009683-sec-0001"> <h3 class="title" id="CD009683-sec-0001">Background</h3> <p>Essential tremor (ET) is one of the most common movement disorders. The management is primarily based on pharmacological agents and in clinical practice propranolol and primidone are considered the first‐line therapy. However, these treatments can be ineffective in 25% to 55% of people and are frequently associated with serious adverse events (AEs). For these reasons, it is worthwhile evaluating other treatments for ET. Topiramate has been suggested as a potentially useful agent for the treatment of ET but there is uncertainty about its efficacy and safety. </p> </section> <section id="CD009683-sec-0002"> <h3 class="title" id="CD009683-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of topiramate in the treatment of ET.</p> </section> <section id="CD009683-sec-0003"> <h3 class="title" id="CD009683-sec-0003">Search methods</h3> <p>We carried out a systematic search without language restrictions to identify all relevant trials in the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (January 1966 to January 2017), Embase (January 1988 to January 2017), National Institute for Health and Care Excellence (1999 to January 2017), ClinicalTrials.gov (1997 to January 2017) and World Health Organization International Clinical Trials Registry Platform (ICTRP; 2004 to January 2017). We searched BIOSIS Citation Index (2000 to January 2017) for conference proceedings. We handsearched grey literature and the reference lists of identified studies and reviews. </p> </section> <section id="CD009683-sec-0004"> <h3 class="title" id="CD009683-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials (RCTs) of topiramate versus placebo/open control or any other treatments. We included studies in which the diagnosis of ET was made according to accepted and validated diagnostic criteria. We excluded studies conducted in people presenting with secondary forms of tremor or reporting only neurophysiological parameters to assess outcomes. </p> </section> <section id="CD009683-sec-0005"> <h3 class="title" id="CD009683-sec-0005">Data collection and analysis</h3> <p>Two review authors independently collected and extracted data using a data collection form. We assessed the risk of bias and the quality of evidence. We used a fixed‐effect meta‐analysis for data synthesis. </p> </section> <section id="CD009683-sec-0006"> <h3 class="title" id="CD009683-sec-0006">Main results</h3> <p>This review included three trials comparing topiramate to placebo (309 participants). They were all at high overall risk of bias. The quality of evidence ranged from very low to low. Compared to placebo, participants treated with topiramate showed a significant improvement in functional disability and an increased risk of withdrawal (risk ratio (RR) 1.78, 95% confidence interval (CI) 1.23 to 2.60). There were more AEs for topiramate‐treated participants, particularly paraesthesia, weight loss, appetite decrease and memory difficulty. </p> </section> <section id="CD009683-sec-0007"> <h3 class="title" id="CD009683-sec-0007">Authors' conclusions</h3> <p>This systematic review highlighted the presence of limited data and very low to low quality evidence to support the apparent efficacy and the occurrence of treatment‐limiting AEs in people with ET treated with topiramate. Further research to assess topiramate efficacy and safety on ET is needed. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009683-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009683-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009683-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009683-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009683-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/pl#CD009683-abs-0007">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009683-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009683-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009683-abs-0004" lang="en"> <h3>Use of topiramate for the treatment of essential tremor</h3> <p><b>Review question</b> </p> <p>The authors of this review tried to assess the effectiveness and safety of topiramate in people with essential tremor. </p> <p><b>Background</b> </p> <p>Essential tremor is a type of uncontrollable shaking or trembling of parts of the body. Although it is not harmful in terms of its effect on life expectancy, it generally gets worse and may be disabling. Treatment is usually with medicines (called propranolol and primidone), which may not work in a quarter to a half of people with essential tremor. Some specialists have suggested that another medicine, topiramate, could be useful for treating the condition. </p> <p><b>Study characteristics</b> </p> <p>We searched medical databases for studies of topiramate compared with placebo (a pretend tablet) or any other medicine in adults with essential tremor. We found three studies comparing topiramate versus placebo, involving 309 participants with moderate to severe essential tremor. </p> <p><b>Key results</b> </p> <p>The effect of topiramate on daily activities, risk of stopping treatment and side effects was uncertain because the quality of evidence was very low to low. </p> <p><b>Quality of evidence</b> </p> <p>We only found a few studies that had problems with their methods so we could not make firm conclusions about how well topiramate works and if it has side effects. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009683-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009683-sec-0090"></div> <h3 class="title" id="CD009683-sec-0091">Implications for practice</h3> <section id="CD009683-sec-0091"> <p>Based on the currently available studies, this Cochrane Review can provide no firm conclusions about the use of topiramate for the treatment of essential tremor (ET). Even if the included trials supported the efficacy of this treatment, the high risk of bias could have influenced the results obtained. Considering safety, it appeared that the use of topiramate was treatment limiting due to the presence of important adverse events. We should highlight that ET is a lifelong condition requiring a long‐duration of treatment. However, no statement can be made on long‐term efficacy and safety of topiramate considering the short follow‐up of the trials included. There are insufficient high quality data to support definitive conclusions regarding benefit‐risk balance. </p> </section> <h3 class="title" id="CD009683-sec-0092">Implications for research</h3> <section id="CD009683-sec-0092"> <p>Even though management of ET is still unsatisfactory for many people, research on different treatment options seems to have reduced over the years and clinical trials with adequate methodology are lacking. The potential role of topiramate in ET treatment, highlighted in 2008, has not been investigated in depth. Future trials should have a larger sample, a longer duration, a high quality methodology (proper randomisation, blinding and reporting) and should select clinically relevant primary outcomes (functional). The inclusion of already treated participants should be better controlled by stratifying during randomisation and by performing adequate subgroup analysis. A new study, aimed at analysing the efficacy and safety of topiramate for ET, should also evaluate the benefit‐risk of lower topiramate doses also assessing the minimum efficacious dose. Finally, trials of direct comparison between topiramate and propranolol and between topiramate and primidone might produce relevant data. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009683-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009683-sec-0029"></div> <div class="table" id="CD009683-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Topiramate for essential tremor</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Topiramate for essential tremor</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with essential tremor </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> topiramate </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Topiramate</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Functional disability</b> </p> <p><b>(follow‐up duration 24 weeks)</b> </p> <p>TRS subscale B score (motor tasks)</p> <p>TRS subscale C score (functional disability)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in the control group was<br/> <b>4.9 points</b> for TRS subscale B and <b>3.7 points</b> for TRS subscale C. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in the intervention groups was<br/> <b>5.4 (2.38 to 8.42) points greater</b> for TRS subscale B and <b>5.7 (2.66 to 8.74) points greater</b> for TRS subscale C. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>223<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Study withdrawal</b> </p> <p><b>(follow‐up duration 10 to 24 weeks)</b> </p> <p>Number of participants withdrawn from the study</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.78</b> <br/> (1.23 to 2.60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>285<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>217 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>347 per 1000</b> <br/> (252 to 458) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events</b> </p> <p><b>(follow‐up duration 24 weeks)</b> </p> <p>Number of AEs</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>221<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 AEs per 105 participants</b> <br/> (mean 0.7 AEs reported by each participant) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>195 AEs per 116 participants</b> <br/> (mean of 1.7 AEs reported by each participant) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>AE:</b> adverse event; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>TRS:</b> Tremor Rating Scale. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded due to serious risk of bias: high number of study withdrawals (attrition bias); blinding of outcome assessment probably revealed by the presence of serious AEs in the topiramate group: trials should be regarded as single blind (detection bias); potential conflicts of interest due to the presence of authors sponsored by pharmaceutical companies.<br/> <sup>2</sup> Downgraded due to serious indirectness: uncertainty about the relevance of the reported TRS‐score changes as indicators of important clinical improvement. </p> <p><sup>3</sup> Downgraded due to imprecision: small sample size (&lt; 300 participants) and small number of included studies (three). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009683-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009683-sec-0030"></div> <section id="CD009683-sec-0031"> <h3 class="title" id="CD009683-sec-0031">Description of the condition</h3> <p>Essential tremor (ET) is one of the most common movement disorders, with an overall estimated prevalence ranging from 0.9% to 2.2%, even higher among people over 65 years of age (4.6%) (<a href="./references#CD009683-bbs2-0039" title="LouisED , FerreiraJJ . How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Movement Disorders2010;25(5):534‐41. ">Louis 2010</a>). </p> <p>It is characterised by postural and kinetic tremor involving the arms and less commonly the head, lower limbs and voice (<a href="./references#CD009683-bbs2-0038" title="LouisED . Essential tremor. Lancet Neurology2005;4:100‐10. ">Louis 2005</a>), frequently accompanied by a family history of a similar tremor. However, ET is a heterogeneous disorder and there is little agreement among specialists regarding both clinical definition and diagnostic criteria (<a href="./references#CD009683-bbs2-0031" title="JankovicJ . Essential tremor: a heterogeneous disorder. Movement Disorders2002;17:638‐44. ">Jankovic 2002</a>). Although benign in term of its effect on life expectancy, it often causes embarrassment and, in a small percentage of people, also serious disability (<a href="./references#CD009683-bbs2-0015" title="BusenbarkKL , NashJ , NashS , HubbleJP , KollerWC . Is essential tremor benign?. Neurology1991;41:1982‐3. ">Busenbark 1991</a>; <a href="./references#CD009683-bbs2-0032" title="KollerW , BiaryN , ConeS . Disability in essential tremor: effect of treatment. Neurology1986;36:1001‐4. ">Koller 1986</a>). Moreover, symptoms are typically progressive and potentially disabling, sometimes forcing people to change job or seek early retirement (<a href="./references#CD009683-bbs2-0019" title="DeuschlG , KollerWC . Essential tremor. Neurology2000;54 Suppl 4:1. ">Deuschl 2000</a>). The treatment is primarily based on pharmacological agents, although surgical intervention may be an option in the most disabling cases. Pharmacotherapy may be used to improve function or reduce the embarrassment associated with ET, but treatment should be tailored to the person's level of disability. Although propranolol and primidone are well‐established agents used in clinical practice for the treatment of ET, additional medications may be useful in reducing tremor (<a href="./references#CD009683-bbs2-0053" title="SullivanKL , HauserRA , ZesiewiczTA . Essential Tremor Epidemiology, Diagnosis and Treatment. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. ">Sullivan 2004</a>). In fact, even though it has been reported that both propranolol and primidone improve tremor in about two‐thirds of people (<a href="./references#CD009683-bbs2-0033" title="KollerWC , Vetere‐OverfieldB . Acute and chronic effects of propranolol and primidone in essential tremor. Neurology1989;39:1587‐8. ">Koller 1989</a>; <a href="./references#CD009683-bbs2-0056" title="WasielewskiPG , BurnsJM , KollerWC . Pharmacologic treatment of tremor. Movement Disorders1998;13 Suppl 3:90‐100. ">Wasielewski 1998</a>), these agents tend to lose efficacy over time (<a href="./references#CD009683-bbs2-0036" title="LouisED . Clinical practice, essential tremor. New England Medical Journal2001;342(12):887‐91. ">Louis 2001a</a>). In addition, their use is limited, particularly among elderly people (aged over 70 years) (<a href="./references#CD009683-bbs2-0061" title="ZesiewiczTA , EncarnacionE , HauserRA . Management of essential tremor. Current Neurology and Neuroscience Reports2002;2:324‐30. ">Zesiewicz 2002</a>), due to adverse effects (AEs) and their interactions with medications commonly used in these people (e.g. digoxin, calcium channel blockers and antiarrhythmics) (<a href="./references#CD009683-bbs2-0025" title="HanstenPD , HornJR . In: WickershamRM , O’Dell , JA editor(s). Managing Clinically Important Drug Interactions. St Louis: Facts &amp; Comparisons, 2004. ">Hansten 2004</a>). Anticonvulsants have been suggested as potentially useful agents for the treatment of ET and they are usually well tolerated (<a href="./references#CD009683-bbs2-0041" title="OndoW , HunterC , VuongKD , SchwartzK , JankovicJ . Gabapentin for essential tremor: a multiple‐dose, double‐blind, placebo‐controlled trial. Movement Disorders2000;15(4):678‐82. ">Ondo 2000</a>; <a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a>; <a href="./references#CD009683-bbs2-0043" title="PahwaR , LyonsK , HubbleJP , BusenbarkK , RienerthJD , PahwaA , et al. Double‐blind placebo‐controlled study of gabapentin in essential tremor. Movement Disorders1998;13:465‐7. ">Pahwa 1998</a>; <a href="./references#CD009683-bbs2-0063" title="ZesiewiczTA , WardCL , HauserRA , Sanchez‐RamosJ , StaffettiJF , SullivanKL . A double‐blind placebo‐controlled trial of zonisamide (Zonegran) in the treatment of essential tremor. Movement Disorders2007;22:279‐82. ">Zesiewicz 2007a</a>). </p> </section> <section id="CD009683-sec-0032"> <h3 class="title" id="CD009683-sec-0032">Description of the intervention</h3> <p>Topiramate is a sulphamate substituted monosaccharide, derived from D‐fructose. The pharmacological potential of topiramate is the result of multiple mechanisms of action: it inhibits sodium conductance in neural membranes, enhances the α1‐subunit of the gamma‐aminobutyric acid (GABA‐A) receptor activity, increases GABA‐mediated chloride influx into neurons, and reduces the activity of L‐type high voltage‐activated calcium channels and of the glutamate receptor amino‐3‐hydroxy‐5‐methylisoxazole‐4‐proprionic acid (AMPA) subtype. Topiramate is rapidly absorbed orally, with a bioavailability approaching 100%. The time to peak blood levels is about two hours and it is widely distributed in tissues, including the brain. It is metabolised in the liver by the P450 microsomal enzymes, and eliminated via renal mechanism, with a plasma elimination half‐life between 19 and 25 hours, independently of dose. Despite being a mild inhibitor of P450 isoenzyme CYP2C19, in practice topiramate does not affect the steady state of other drugs (<a href="./references#CD009683-bbs2-0049" title="ShorvonSD . Handbook of Epilepsy Treatment. 2nd Edition. Oxford: Blackwell, 2005. ">Shorvon 2005</a>). </p> </section> <section id="CD009683-sec-0033"> <h3 class="title" id="CD009683-sec-0033">How the intervention might work</h3> <p>ET may be caused by a deficiency in the GABA‐A receptor, as demonstrated in a knockout model in mice (<a href="./references#CD009683-bbs2-0034" title="KralicJE , CriswellHE , OstermanJL , O'BuckleyTK , WilkieME , MatthewsDB , et al. Genetic essential tremor in gamma‐aminobutyric acid A receptor alpha1 subunit knockout mice. Journal of Clinical Investigation2005;115:774‐9. ">Kralic 2005</a>). This mechanism suggests that the GABAergic system could be a potential target for pharmacotherapy, and that GABA‐A receptor agonists may be effective in ET (<a href="./references#CD009683-bbs2-0034" title="KralicJE , CriswellHE , OstermanJL , O'BuckleyTK , WilkieME , MatthewsDB , et al. Genetic essential tremor in gamma‐aminobutyric acid A receptor alpha1 subunit knockout mice. Journal of Clinical Investigation2005;115:774‐9. ">Kralic 2005</a>; <a href="./references#CD009683-bbs2-0044" title="PahwaR , LyonsKE . Essential tremor: differential diagnosis for the development of novel therapeutics. American Journal of Medicine2003;115:134‐42. ">Pahwa 2003</a>). In fact, considering their mechanisms of action, all anticonvulsants that enhance GABAergic neurotransmission could be effective in the treatment of ET. A positive effect of alprazolam (<a href="./references#CD009683-bbs2-0028" title="HuberSJ , PaulsonGW . Efficacy of alprazolam for essential tremor. Neurology1988;38:241‐3. ">Huber 1988</a>), clonazepam (<a href="./references#CD009683-bbs2-0054" title="ThompsonC , LangA , ParkesJD , MarsdenCD . A double‐blind trial of clonazepam in benign essential tremor. Clinical Neuropharmacology1984;7:83‐8. ">Thompson 1984</a>), and zonisamide (<a href="./references#CD009683-bbs2-0040" title="MoritaS , MiwaH , KondoT . Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol. Parkinsonism &amp; Related Disorders2005;11:101‐3. ">Morita 2005</a>) on ET, due to enhancement of GABA release, downregulation of the number of GABA reuptake transporter proteins and upregulation of the glutamate transporter EAAC‐1, has been reported (<a href="./references#CD009683-bbs2-0014" title="BialerM , JohannessenSI , KupferbergHJ , LevyRH , PeruccaE , TomsonT . Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (Eilat VII). Epilepsy Research2004;61:1‐48. ">Bialer 2004</a>; <a href="./references#CD009683-bbs2-0055" title="UedaY , DoiT , TokumaruJ , WillmoreLJ . Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Molecular Brain Research2003;116:1‐6. ">Ueda 2003</a>; <a href="./references#CD009683-bbs2-0059" title="YoshidaS , OkadaM , ZhuG , KanekoS . Effects of zonisamide on neurotransmitter exocytosis associated with ryanodine receptors. Epilepsy Research2005;67:153‐62. ">Yoshida 2005</a>). Gabapentin, which may also facilitate GABAergic function, has also been used for ET (<a href="./references#CD009683-bbs2-0041" title="OndoW , HunterC , VuongKD , SchwartzK , JankovicJ . Gabapentin for essential tremor: a multiple‐dose, double‐blind, placebo‐controlled trial. Movement Disorders2000;15(4):678‐82. ">Ondo 2000</a>). With regards to topiramate, several studies showed that its multiple pharmacological activities may contribute to a neurostabilising effect (<a href="./references#CD009683-bbs2-0057" title="WhiteHS . Mechanism of action of newer anticonvulsants. Journal of Clinical Psychiatry2003;62 Suppl 8:5‐8. ">White 2003</a>), including enhancement of GABA activity, modulation of GABA‐A receptors (<a href="./references#CD009683-bbs2-0058" title="WhiteHS . Molecular pharmacology of topiramate: managing seizures and preventing migraine. Headache2005;45:48‐56. ">White 2005</a>), carbonic anhydrase inhibition, antagonism of AMPA receptor activity and blockage of voltage‐dependent calcium and sodium channels (<a href="./references#CD009683-bbs2-0048" title="ShankRP , GardockiJF , StreeterAJ , MryanoffBE . An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics and mechanism of action. Epilepsia2000;41 Suppl 1:3‐9. ">Shank 2000</a>). </p> </section> <section id="CD009683-sec-0034"> <h3 class="title" id="CD009683-sec-0034">Why it is important to do this review</h3> <p>In 2005, the American Academy of Neurology published the practice parameter for ET (<a href="./references#CD009683-bbs2-0062" title="ZesiewiczTA , ElbleR , LouisED , HauserRA , SullivanKL , DeweyRBJr , et al. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology2005;64(12):2008‐20. ">Zesiewicz 2005</a>), basing the recommendation on an arbitrary four‐tiered level of evidence scheme and concluding that propranolol and primidone should be used as first‐line therapy. Topiramate was considered probably effective in reducing tremor, receiving a level B recommendation. In one update, the conclusion on these treatments appeared unchanged (<a href="./references#CD009683-bbs2-0064" title="ZesiewiczTA , ElbleRJ , LouisED , GronsethGS , OndoWG , DeweyRBJr , et al. Evidence‐based guideline update: treatment of essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology2011;77(19):1752‐5. ">Zesiewicz 2011</a>). Another publication based on the use of GRADE system for assessing the quality of evidence and the strength of recommendations, concluded that the potential role of topiramate among first‐line treatments should be considered, assigning strong recommendation with moderate quality of evidence (<a href="./references#CD009683-bbs2-0060" title="ZappiaM , AlbaneseA , BrunoE , ColosimoC , FilippiniG , MartinelliP , et al. Italian Movement Disorders Association (DISMOV‐SIN) Essential Tremor Committee. Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. Journal of Neurology2013;260(3):714‐40. ">Zappia 2013</a>). As primidone or propranolol administration may be limited due to the risk of serious AEs, and as these agents could lose their efficacy in long‐term therapy, it may be worthwhile evaluating treatment alternatives for ET. As there is uncertainty about the efficacy of topiramate, a systematic review aimed at evaluating whether this agent could be an effective alternative for people with ET may generate clinically useful information. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009683-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009683-sec-0035"></div> <p>To assess the efficacy and safety of topiramate in the treatment of ET.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009683-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009683-sec-0036"></div> <section id="CD009683-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009683-sec-0038"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs), both parallel group and cross‐over designs.</p> </section> <section id="CD009683-sec-0039"> <h4 class="title">Types of participants</h4> <p>Adults (aged 16 years or older) with ET diagnosed according to the criteria proposed by the Tremor Investigation Group (<a href="./references#CD009683-bbs2-0012" title="BainP , BrinM , DeuschlG , ElbleR , JankovicJ , FindleyL , et al. Criteria for the diagnosis of essential tremor. Neurology2000;54 Suppl 4:7. ">Bain 2000a</a>), the Consensus Statement of the Movement Disorder Society on Tremor (<a href="./references#CD009683-bbs2-0018" title="DeuschlG , BainP , BrinM . Consensus statement of the Movement Disorder Society on tremor. Ad Hoc Scientific Committee. Movement Disorders1998;13 Suppl 3:2‐23. ">Deuschl 1998</a>), or previous accepted and validated clinical criteria (<a href="./references#CD009683-bbs2-0016" title="ChouinardS , LuoisED , FahnS . Agreement among movement disorder specialists on the clinical diagnosis of essential tremor. Movement Disorders1997;12(6):973‐6. ">Chouinard 1997</a>; <a href="./references#CD009683-bbs2-0024" title="HaererAF , AndersonDW , SchoenbergBS . Prevalence of essential tremor: results from the Copiah county study. Archives of Neurology1992;39:750‐1. ">Haerer 1992</a>; <a href="./references#CD009683-bbs2-0035" title="LouisED , FordB , LeeH . Diagnostic criteria for essential tremor. Archives of Neurology1998;55:823‐8. ">Louis 1998</a>; <a href="./references#CD009683-bbs2-0045" title="RajputAH , OffordKP , BeardCM , KurlandLT . Essential tremor in Rochester, Minnesota: a 45‐year study. Journal of Neurology, Neurosurgery and Psychiatry1984;47:466‐70. ">Rajput 1984</a>; <a href="./references#CD009683-bbs2-0047" title="SalemiG , SavettieriG , RoccaWA , MeneghiniF , SaporitoV , MorganteL , et al. Prevalence of essential tremor: a door to‐door survey in Terrasini, Sicily. Neurology1994;44:61‐4. ">Salemi 1994</a>; <a href="./references#CD009683-bbs2-0051" title="SnowB , WiensM , HertzmanC , CalneD . A community survey of Parkinson's disease. Canadian Medical Association Journal1989;141:418‐24. ">Snow 1989</a>). </p> <p>We excluded from our review studies considering participants with a secondary form of tremor (e.g. thyroid disease). </p> </section> <section id="CD009683-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Topiramate for ET compared to: placebo/open control; any other pharmacological treatment, by any dose or route of administration. </p> </section> <section id="CD009683-sec-0041"> <h4 class="title">Types of outcome measures</h4> <p>We excluded studies that reported only neurophysiological parameters (e.g. electromyographic recordings, accelerometry, spirography, digitising tablets) to assess outcomes. These instrumental tests have important limitations since their accuracy and reproducibility are not well established. Moreover, neurophysiological measures are only weakly correlated with a person's functional disability (<a href="./references#CD009683-bbs2-0010" title="BainPG . The effectiveness of treatments for essential tremor. Neurology1997;3:305‐21. ">Bain 1997</a>; <a href="./references#CD009683-bbs2-0013" title="BainPG . Tremor assessment and quality of life measurements. Neurology2000;54 Suppl 4:26‐9. ">Bain 2000b</a>). </p> <section id="CD009683-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD009683-list-0001"> <li> <p>Functional disability component related to tremor, measured by the Fahn‐Tolosa‐Marin Tremor Rating Scale (TRS) subscales B and C (<a href="./references#CD009683-bbs2-0021" title="FahnS , TolosaE , MarinC . Clinical rating scale for tremor. In: JankovicJ , TolosaE editor(s). Parkinson' s Disease and Movement Disorders. Baltimore: Williams &amp; Wilkins, 1993:225‐34. ">Fahn 1993</a>) at the end of follow‐up. </p> </li> </ul> </p> <p>The TRS assesses rest, postural and action tremor. TRS total score is derived from three TRS subscales: </p> <p> <ul class="plain" id="CD009683-list-0002"> <li> <ul id="CD009683-list-0003"> <li> <p>examiner‐reported upper limb postural and action tremor severity (amplitude), four elements; </p> </li> <li> <p>examiner‐reported ability to perform specific motor tasks (writing, drawing and pouring with dominant and non‐dominant hands), nine elements; </p> </li> <li> <p>participant‐reported functional disabilities due to tremor (eating, speaking, drinking, hygiene, dressing, writing, working and social activities), eight elements. </p> </li> </ul> </li> </ul> </p> <p>Each subscale element is rated from 0 to 4 (none to severe tremor) giving a maximum score of 16, 36 and 32 for each subscale. The overall TRS score is the sum of individual elements calculated as a fraction of the subscale's maximum score and converted to a 100‐point scale (0 to 100). </p> <p>We considered other validated scales to assess and measure tremor severity, such as the Unified Tremor Rating Scale (UTRA) (<a href="./references#CD009683-bbs2-0022" title="FindleyLJ , KollerW . Definitions and behavioural classifications. In: FindleyLG , KollerW editor(s). Handbook of Tremor Disorders. New York: Dekker, 1995:1‐5. ">Findley 1995</a>; <a href="./references#CD009683-bbs2-0030" title="JankovicJ , SchwartzK , ClemenceJ . A randomized, double‐blind, placebo controlled study to evaluate botulinum toxin type A in essential tremor. Movement Disorders1996;11:250‐6. ">Jankovic 1996</a>), the Bain scale (<a href="./references#CD009683-bbs2-0011" title="BainPG . Clinical measurement of tremor. Movement Disorders1998;13 Suppl 3:77‐80. ">Bain 1998</a>), and the Washington Heights‐Inwood Genetic Study of Essential Tremor (WHIGET) rating scale (<a href="./references#CD009683-bbs2-0037" title="LouisED , BarnesL , WendtKJ , FordB , SangiorgioM , TabbalS , et al. A teaching videotape for the assessment of essential tremor. Movement Disorders2001;16:89‐93. ">Louis 2001b</a>). </p> <p> <ul id="CD009683-list-0004"> <li> <p>Withdrawal, defined in a standard manner, and number of AEs associated with treatment.</p> </li> </ul> </p> <p>To analyse the main causes of study withdrawal, we grouped participant's reason of discontinuation using the following categories: lack of efficacy, AEs, other reasons (including participant choice, lost to follow‐up, non‐compliance and unknown reasons). We also grouped AEs considering the symptom presented: paraesthesia, weight loss, nausea, fatigue, appetite decrease, memory difficulty, dizziness, diarrhoea and headache. </p> </section> <section id="CD009683-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD009683-list-0005"> <li> <p>Tremor severity, measured by:</p> </li> </ul> <ul class="plain" id="CD009683-list-0006"> <li> <ul id="CD009683-list-0007"> <li> <p>Fahn‐Tolosa‐Marin TRS subscale A and total score;</p> </li> <li> <p>participant self‐rated severity score: Patient Global Impression (PGI);</p> </li> <li> <p>clinician‐rated global score: Clinical Global Impression (CGI).</p> </li> </ul> </li> </ul> <ul id="CD009683-list-0008"> <li> <p>Quality of life (QoL) measured by:</p> </li> </ul> <ul class="plain" id="CD009683-list-0009"> <li> <ul id="CD009683-list-0010"> <li> <p>a validated QoL scale or questionnaire: 36‐item Short Form (SF‐36), EuroQol.</p> </li> </ul> </li> </ul> </p> </section> </section> </section> <section id="CD009683-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <p>We carried out a systematic search with no language restrictions to identify all relevant published and unpublished RCTs. </p> <section id="CD009683-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases for relevant trials.</p> <p> <ul id="CD009683-list-0011"> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL) (2017, Issue 1).</p> </li> <li> <p>MEDLINE (January 1966 to January 2017).</p> </li> <li> <p>Embase (January 1988 to January 2017).</p> </li> <li> <p>National Institute for Health and Care Excellence (NICE) (1999 to January 2017).</p> </li> <li> <p>ClinicalTrials.gov (1997 to January 2017).</p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (2004 to January 2017). </p> </li> </ul> </p> <p>We additionally searched BIOSIS Citation Index (2000 to January 2017) for conference proceedings. </p> <p>We based the search strategies for each database on the strategy developed for MEDLINE, revising it appropriately for each database to take into account the differences in controlled vocabulary and syntax rules. See <a href="./appendices#CD009683-sec-0096">Appendix 1</a> and <a href="./appendices#CD009683-sec-0097">Appendix 2</a>. </p> </section> <section id="CD009683-sec-0046"> <h4 class="title">Searching other resources</h4> <p>In addition to the electronic searches, we:</p> <p> <ul id="CD009683-list-0012"> <li> <p>handsearched reference lists of all available review articles and primary studies;</p> </li> <li> <p>handsearched the references quoted in the most recent abstract books of European Federation of Neurological Societies (2005 to 2016), American Academy of Neurology (2003 to 2016), American Neurological Association (2006 to 2016), World Federation of Neurology (2008 to 2016) and of The Movement Disorder Society (2003 to 2016); </p> </li> <li> <p>contacted the corresponding authors of relevant trials;</p> </li> <li> <p>contacted drug manufacturers for information on ongoing trials.</p> </li> </ul> </p> </section> </section> <section id="CD009683-sec-0047"> <h3 class="title" id="CD009683-sec-0047">Data collection and analysis</h3> <p>Two review authors (EB and RA) independently assessed the titles and abstracts of all the studies identified by the electronic searching or handsearching. We obtained the full text of potentially relevant trials. </p> <section id="CD009683-sec-0048"> <h4 class="title">Selection of studies</h4> <p>After reading the abstracts, two review authors (EB and RA) independently selected the eligible articles and scrutinised the full texts of the selected studies and decided which trials met the inclusion criteria for this review. We resolved any disagreements concerning inclusion and exclusion of trials by discussion. </p> </section> <section id="CD009683-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (EB and RA) independently extracted the following data, using a data collecting form: </p> <p> <ul id="CD009683-list-0013"> <li> <p>trial design;</p> </li> <li> <p>randomisation methods;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of treatments and assessments;</p> </li> <li> <p>comparability of treatment groups in terms of demographic and clinical characteristics;</p> </li> <li> <p>inclusion and exclusion criteria;</p> </li> <li> <p>duration of treatment;</p> </li> <li> <p>length of follow‐up;</p> </li> <li> <p>outcome measures (use of validated scales);</p> </li> <li> <p>number of withdrawals and respective causes;</p> </li> <li> <p>description of AEs.</p> </li> </ul> </p> <p>We resolved disagreements on extracted data by discussion.</p> </section> <section id="CD009683-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The review authors independently judged trial quality according to the methods set out in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009683-bbs2-0027" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <p>We considered seven specific domains:</p> <p> <ul id="CD009683-list-0014"> <li> <p>random sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants and personnel;</p> </li> <li> <p>blinding of outcome assessment;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective reporting;</p> </li> <li> <p>other sources of bias.</p> </li> </ul> </p> <p>Two review authors (EB and RA) independently assessed the risk of bias of each included study and resolved any disagreements by discussion to reach consensus. The overall assessment of risk of bias was based on recommendations reported in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009683-bbs2-0027" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). If one or more domains were assessed at high risk of bias, we rated the overall score as high. If all domains were rated as having a low risk of bias, the overall score was considered low. All the other combinations were rated as unclear overall risk of bias. </p> <p>We considered the risk of bias in included studies in the interpretation of primary outcome results using the GRADE approach. We examined consistency, directness and precision to grade the quality of evidence according to GRADE guidelines (<a href="./references#CD009683-bbs2-0023" title="SchünemannH , BrożekJ , GuyattG , OxmanA . The Grading of Recommendations Assessment, Development and Evaluation (GRADE) profile (pro) and Guideline development tool (GDT). Version 3.6. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro</a>). We rated overall quality of evidence as 'high', 'moderate', 'low' and 'very low'. Through the GRADE approach, RCTs were assigned an initial high rating that was subsequently modified by the sequential judgement of limitations, inconsistency of the results, indirectness of the evidence, imprecision of data and presence of publication bias. The primary outcomes considered were functional disability related to tremor, withdrawals and number of AEs. Two review authors (EB and RA) independently graded the body of evidence using GRADE guidance and resolving discrepancies through discussion aimed at achieving consensus. </p> </section> <section id="CD009683-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed measurement scales to assess ET as continuous variables. We calculated and expressed the intervention effect as mean differences (MD) and standard deviations (SD) for individual studies and for the pooled estimates with 95% confidence intervals (CI). We used changes from baseline for all continuous variables. </p> <p>We expressed categorical variables (number of withdrawals and number of AEs) as frequencies and percentages. </p> </section> <section id="CD009683-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>To avoid the 'carry‐over' effect that can induce alteration of the response to subsequent treatment in cross‐over studies (<a href="./references#CD009683-bbs2-0050" title="SibbaldB , RobertsC . Understanding controlled trials: crossover trials. BMJ1998;316(7146):1719‐20. ">Sibbald 1998</a>), we used only data from the first treatment phase after randomisation. </p> </section> <section id="CD009683-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>To estimate the effect of participant withdrawals or loss to follow‐up on primary outcomes, we extracted available information about incomplete data and about the intention‐to‐treat analysis performed. We only included data for participants whose results were reported. We calculated the frequency of withdrawals for each treatment group for separate and pooled studies. We considered the impact of missing data during the assessment of risk of bias. </p> </section> <section id="CD009683-sec-0054"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed reporting biases concerning both primary and secondary outcomes. We planned to assess reporting biases comparing the outcomes reported in the study protocol with the outcomes in the published study. If the study protocol was not available, we compared the outcomes listed or mentioned in the methods section of the article with those whose results were reported. </p> </section> <section id="CD009683-sec-0055"> <h4 class="title">Data synthesis</h4> <p>Within the different comparisons, we calculated MD and SD to assess efficacy and frequencies and percentages for withdrawals and AEs with 95% CI. </p> <p>Provided that, for each comparison, an outcome of interest was reported by at least two included studies, we combined data in a meta‐analysis. There were no restrictions based on risk of bias. We used a fixed‐effect model to combine data. </p> <p>We used inverse variance methods for continuous outcomes and measurement scales. Difference between treatment groups was compared as MD. For dichotomous outcomes (withdrawals, AEs), we expressed the effect of intervention as risk ratio (RR). We also used risk differences (RDs) to compare treatment groups. We estimated pooled RR using the Mantel‐Haenszel method. We used Review Manager 5 software for data management and analysis (<a href="./references#CD009683-bbs2-0046" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We reported 95% CI. </p> </section> <section id="CD009683-sec-0056"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to investigate heterogeneity by conducting subgroup analyses based on prespecified study characteristics. We planned to investigate potential positive or negative interactions between topiramate and other anti‐tremor medications on primary outcomes, performing a subgroup analysis of trials in which only the experimental anti‐tremor medication was allowed (topiramate/placebo/other treatment) and of trials including participants using other concomitant anti‐tremor medications during the study period. For trials in which treatment effects were reported for more than one dose, we planned to investigate the effect of the different doses reported separately. We assessed heterogeneity using the I<sup>2</sup> statistic (<a href="./references#CD009683-bbs2-0026" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). </p> </section> <section id="CD009683-sec-0057"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analyses to investigate the effect of inclusion or exclusion of studies at high risk of bias, by removing single trials at high risk of bias. We planned to use best‐ and worst‐case scenarios for taking into account missing binary data. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009683-sec-0058" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009683-sec-0058"></div> <section id="CD009683-sec-0059"> <h3 class="title">Description of studies</h3> <section id="CD009683-sec-0060"> <h4 class="title">Results of the search</h4> <p>The search of electronic databases retrieved 37 references. We identified one additional study as a result of screening reference lists of review articles. We excluded 26 studies after reading titles and abstracts: 16 were published as review articles, six references were duplicates, three were observational studies and one included people with neuropsychiatric problems. We selected 12 studies aimed at evaluating topiramate treatment for ET and obtained the full text. </p> <p><a href="#CD009683-fig-0001">Figure 1</a> shows a flowchart of the results of the electronic search. </p> <div class="figure" id="CD009683-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009683-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_n/nCD009683-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD009683-sec-0061"> <h4 class="title">Included studies</h4> <p>Three studies were eligible for this review (<a href="./references#CD009683-bbs2-0001" title="Carrasco VargasH , Castellanos RodriguezJ , Aceves RodriguezR . Prospective double blind study of the use of topiramate vs. placebo in the treatment of essential tremor [Estudio prospectivo doble ciego del uso de topiramato vs. placebo en el tratamiento de temblor esencial]. Neurologia, Neurocirugia, Psiquiatria2011;44:1‐5. ">Carrasco Vargas 2011</a>; <a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a>; <a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a>) (see <a href="./references#CD009683-sec-0106" title="">Characteristics of included studies</a> table). </p> <section id="CD009683-sec-0062"> <h5 class="title">Trial design</h5> <p><a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a> and <a href="./references#CD009683-bbs2-0001" title="Carrasco VargasH , Castellanos RodriguezJ , Aceves RodriguezR . Prospective double blind study of the use of topiramate vs. placebo in the treatment of essential tremor [Estudio prospectivo doble ciego del uso de topiramato vs. placebo en el tratamiento de temblor esencial]. Neurologia, Neurocirugia, Psiquiatria2011;44:1‐5. ">Carrasco Vargas 2011</a> were double‐blind parallel RCTs; <a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a> reported pooled data from three cross‐over studies (<a href="./references#CD009683-bbs2-0017" title="ConnorGS . A double‐blind placebo‐controlled trial of topiramate treatment for essential tremor. Neurology2002;59(1):132‐4. ">Connor 2002</a>, and Edwards K and Tarsy D, unpublished data) that "<i>featured the same design and inclusion/exclusion criteria</i>". The statistical analysis used to pool the data from the three trials was not reported in the manuscript. The authors adjusted the primary analysis (analysis of covariance for a two‐period, two‐treatment cross‐over study) for baseline characteristics and source centre of each participant. Considering that, even after contact with the authors, additional data were not available and that <a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a> did not provide sufficient information for identifying and extracting data obtained from the three different trials (including <a href="./references#CD009683-bbs2-0017" title="ConnorGS . A double‐blind placebo‐controlled trial of topiramate treatment for essential tremor. Neurology2002;59(1):132‐4. ">Connor 2002</a>), we retained only the pooled study (<a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a>). Additionally, <a href="./references#CD009683-bbs2-0029" title="HulihanJ , ConnorGS , Shu‐ChenW . Topiramate in essential tremor: pooled data from a double‐blind, placebo‐controlled, crossover trial. American Academy of Neurology2003;Abstracts:P04.068. ">Hulihan 2003</a> and <a href="./references#CD009683-bbs2-0042" title="OndoWG , JankovicJ , StacyMA . Topiramate for essential tremor. Neurology2004;62:LBS.004. ">Ondo 2004</a> reported preliminary results further presented and detailed in other studies included in this review (<a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a>; <a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a>) and were not retained for the same reasons. </p> <p>All the studies compared topiramate with placebo. The duration of the study was two weeks in <a href="./references#CD009683-bbs2-0001" title="Carrasco VargasH , Castellanos RodriguezJ , Aceves RodriguezR . Prospective double blind study of the use of topiramate vs. placebo in the treatment of essential tremor [Estudio prospectivo doble ciego del uso de topiramato vs. placebo en el tratamiento de temblor esencial]. Neurologia, Neurocirugia, Psiquiatria2011;44:1‐5. ">Carrasco Vargas 2011</a>, 10 weeks in <a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a>, and 24 weeks in <a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a>. </p> </section> <section id="CD009683-sec-0063"> <h5 class="title">Participants</h5> <p>The studies included people with definite upper‐limb ET according to criteria proposed by Tremor Investigation Group (<a href="./references#CD009683-bbs2-0012" title="BainP , BrinM , DeuschlG , ElbleR , JankovicJ , FindleyL , et al. Criteria for the diagnosis of essential tremor. Neurology2000;54 Suppl 4:7. ">Bain 2000a</a>). <a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a> included also 12 participants with head tremor. Studies included 223 participants (<a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a>), 62 participants (<a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a>), and 24 participants (<a href="./references#CD009683-bbs2-0001" title="Carrasco VargasH , Castellanos RodriguezJ , Aceves RodriguezR . Prospective double blind study of the use of topiramate vs. placebo in the treatment of essential tremor [Estudio prospectivo doble ciego del uso de topiramato vs. placebo en el tratamiento de temblor esencial]. Neurologia, Neurocirugia, Psiquiatria2011;44:1‐5. ">Carrasco Vargas 2011</a>). Baseline TRS total scores were 38.7 (SD 12.4) (<a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a>), 36.8 (SD 17.8) (<a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a>), and 27.1 (SD 10.9) (<a href="./references#CD009683-bbs2-0001" title="Carrasco VargasH , Castellanos RodriguezJ , Aceves RodriguezR . Prospective double blind study of the use of topiramate vs. placebo in the treatment of essential tremor [Estudio prospectivo doble ciego del uso de topiramato vs. placebo en el tratamiento de temblor esencial]. Neurologia, Neurocirugia, Psiquiatria2011;44:1‐5. ">Carrasco Vargas 2011</a>). <a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a> reported a disease duration of 24 (SD 17) years. Age ranged between 18 and 80 years. Moreover, the studies included people treated with a stable anti‐tremor medication for at least two to four weeks before randomisation. The co‐therapy (mainly beta‐blockers and benzodiazepine in <a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a> and beta‐blockers and primidone in <a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a>) was maintained throughout the study period. Both <a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a> and <a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a> excluded people with other neurological causes of tremor (degenerative disease, nervous system trauma, epilepsy, psychogenic tremor, alcohol or drugs abuse) and concomitant systemic disease (liver disease, endocrinological disease, renal stones, renal insufficiency, nephrolithiasis), occurrence of AEs during previous treatment with topiramate or psychiatric disorders. <a href="./references#CD009683-bbs2-0001" title="Carrasco VargasH , Castellanos RodriguezJ , Aceves RodriguezR . Prospective double blind study of the use of topiramate vs. placebo in the treatment of essential tremor [Estudio prospectivo doble ciego del uso de topiramato vs. placebo en el tratamiento de temblor esencial]. Neurologia, Neurocirugia, Psiquiatria2011;44:1‐5. ">Carrasco Vargas 2011</a> included participant between 18 and 80 years. Participants' general characteristics and disease duration were not reported. </p> </section> <section id="CD009683-sec-0064"> <h5 class="title">Intervention</h5> <p><a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a> included a group of 30 participants receiving topiramate for 10 weeks, followed by 10 weeks of placebo, with a washout period of two weeks between the two treatments. A second group of 32 participants received placebo followed by topiramate. Dosage ranged between 25 mg/day and 400 mg/day divided into two daily doses. </p> <p><a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a> compared a group of 117 participants receiving topiramate for 24 weeks to a group of 106 participants receiving placebo for 24 weeks. Dosage ranged between 25 mg/day and 400 mg/day divided into two daily doses. </p> <p><a href="./references#CD009683-bbs2-0001" title="Carrasco VargasH , Castellanos RodriguezJ , Aceves RodriguezR . Prospective double blind study of the use of topiramate vs. placebo in the treatment of essential tremor [Estudio prospectivo doble ciego del uso de topiramato vs. placebo en el tratamiento de temblor esencial]. Neurologia, Neurocirugia, Psiquiatria2011;44:1‐5. ">Carrasco Vargas 2011</a> compared a group of 12 participants receiving topiramate for two weeks with a group of 12 participants receiving placebo for 12 weeks. Treatment was initiated at the dose of 50 mg divided into two daily doses and increased up to 200 mg/day. The mean treatment dose was not reported. </p> </section> <section id="CD009683-sec-0065"> <h5 class="title">Outcome measures</h5> <p>The three studies used TRS score as the primary efficacy outcome measure. All studies reported TRS total score at baseline and at the study endpoint, while only <a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a> reported TRS subscale A, B and C scores separately. <a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a> also reported a qualitative global rating scale (very good, good, no change, poor, very poor), completed by both investigators and participants. </p> </section> <section id="CD009683-sec-0066"> <h5 class="title">Adverse events</h5> <p>The three studies reported the number of participants experiencing AEs, while only two studies reported the number of participants who withdrew/dropped out (<a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a>; <a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a>). Moreover, <a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a> did not report the number of AEs by period (i.e. before and after the cross‐over) and <a href="./references#CD009683-bbs2-0001" title="Carrasco VargasH , Castellanos RodriguezJ , Aceves RodriguezR . Prospective double blind study of the use of topiramate vs. placebo in the treatment of essential tremor [Estudio prospectivo doble ciego del uso de topiramato vs. placebo en el tratamiento de temblor esencial]. Neurologia, Neurocirugia, Psiquiatria2011;44:1‐5. ">Carrasco Vargas 2011</a> did not report the total number of AEs and the number of withdrawals. </p> </section> </section> <section id="CD009683-sec-0067"> <h4 class="title">Excluded studies</h4> <p>We excluded six studies after reading the full texts (see <a href="./references#CD009683-sec-0107" title="">Characteristics of excluded studies</a> table). Five were case series (<a href="./references#CD009683-bbs2-0004" title="BermejoPE ,  DoradoR . Topiramate in refractory essential tremor. Revista Neurologia2007;45(3):188‐9. ">Bermejo 2007</a>; <a href="./references#CD009683-bbs2-0006" title="Gálvez‐JiménezN , HargreaveM . Topiramate and essential tremor. Annals of Neurology2000;47(6):837‐8. ">Gálvez‐Jimenez 2000</a>; <a href="./references#CD009683-bbs2-0007" title="GattoEM , RocaMC , RainaG , MicheliF . Low doses of topiramate are effective in essential tremor: a report of three cases. Clinical Neuropharmacology2003;26(6):294‐6. ">Gatto 2003</a>; <a href="./references#CD009683-bbs2-0008" title="SiniscalchiA ,  GallelliL ,  De SarroG . Combined topiramate and declorazepam therapy in a patient affected by essential tremor. Parkinsonism &amp; Related Disorders2007;13(2):129‐30. ">Siniscalchi 2007</a>; <a href="./references#CD009683-bbs2-0009" title="ZesiewiczTA . Low‐dose topiramate (Topamax) in the treatment of essential tremor. Clinical Neuropharmacology2007;30(4):247‐8. ">Zesiewicz 2007b</a>). We excluded one study as it reported only electrophysiological data (<a href="./references#CD009683-bbs2-0005" title="FrimaN , GrünewaldRA . A double‐blind, placebo‐controlled, crossover trial of topiramate in essential tremor. Clinical Neuropharmacology2006;29(2):94‐6. ">Frima 2006</a>). </p> </section> </section> <section id="CD009683-sec-0068"> <h3 class="title">Risk of bias in included studies</h3> <p>The results are reported in <a href="#CD009683-fig-0002">Figure 2</a> and <a href="#CD009683-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD009683-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009683-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_n/nCD009683-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD009683-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009683-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_n/nCD009683-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009683-sec-0069"> <h4 class="title">Allocation</h4> <p><a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a> reported methods for sequence generation and allocation concealment and was considered at low risk of bias. <a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a> did not provide enough information to assess if order of receiving treatments was randomised and the risk of bias was unclear. <a href="./references#CD009683-bbs2-0001" title="Carrasco VargasH , Castellanos RodriguezJ , Aceves RodriguezR . Prospective double blind study of the use of topiramate vs. placebo in the treatment of essential tremor [Estudio prospectivo doble ciego del uso de topiramato vs. placebo en el tratamiento de temblor esencial]. Neurologia, Neurocirugia, Psiquiatria2011;44:1‐5. ">Carrasco Vargas 2011</a> did not provide any information regarding randomisation techniques and allocation concealment and reported that participants were randomly assigned either to the treatment or placebo group. This was at high risk of bias. </p> </section> <section id="CD009683-sec-0070"> <h4 class="title">Blinding</h4> <p><a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a> reported adequate methods for blinding personnel, participants and outcome assessors to treatment allocation. <a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a> reported adequate method for blinding of outcome assessors but the authors did not provide enough information to assess the blinding of personnel and participants and therefore risk of performance bias was unclear. <a href="./references#CD009683-bbs2-0001" title="Carrasco VargasH , Castellanos RodriguezJ , Aceves RodriguezR . Prospective double blind study of the use of topiramate vs. placebo in the treatment of essential tremor [Estudio prospectivo doble ciego del uso de topiramato vs. placebo en el tratamiento de temblor esencial]. Neurologia, Neurocirugia, Psiquiatria2011;44:1‐5. ">Carrasco Vargas 2011</a> did not provide information to assess the blinding of outcome assessment and participants and the risk was unclear. </p> </section> <section id="CD009683-sec-0071"> <h4 class="title">Incomplete outcome data</h4> <p>In <a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a>, 45/117 (38.5%) randomised participants in the topiramate group and 23/106 (22%) participants in the placebo group discontinued before study completion. Reasons for missing data were different across groups since more participants withdrew for AEs in the topiramate group. The authors defined the intention‐to‐treat population (108 participants in the topiramate group and 100 participants in the placebo group) as "<i>all randomised patients who took at least one dose of study medication and had at least one on‐treatment efficacy assessment"</i>. This definition implies that an imputation method with a carried forward procedure was used for dealing with missing outcome data and this can lead to serious bias (<a href="./references#CD009683-bbs2-0027" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). In <a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a>, more than 40% of participants in the topiramate group and 25% of participants in the placebo group dropped out, indicating a high risk of bias. Moreover, these authors also imputed missing outcome data with the use of baseline observation carried forward. Both studies were at high risk of attrition bias because neither reported times at which outcomes were genuinely measured in participants for whom outcomes were carried forward. </p> <p><a href="./references#CD009683-bbs2-0001" title="Carrasco VargasH , Castellanos RodriguezJ , Aceves RodriguezR . Prospective double blind study of the use of topiramate vs. placebo in the treatment of essential tremor [Estudio prospectivo doble ciego del uso de topiramato vs. placebo en el tratamiento de temblor esencial]. Neurologia, Neurocirugia, Psiquiatria2011;44:1‐5. ">Carrasco Vargas 2011</a> provided no information regarding treatment discontinuation and it was at unclear risk of bias. </p> </section> <section id="CD009683-sec-0072"> <h4 class="title">Selective reporting</h4> <p>There was no identified reporting bias.</p> </section> <section id="CD009683-sec-0073"> <h4 class="title">Other potential sources of bias</h4> <p>Two studies excluded people with already known hypersensibility to topiramate (<a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a>; <a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a>. Moreover, both the studies were sponsored by and had at least one author affiliated to the pharmaceutical company that marketed topiramate. </p> <p>The findings reported by these two studies should be interpreted with caution in light of the limitations described, in particular the high risk of attrition bias. Moreover, since <a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a> was a multicentre study including among co‐authors and investigators the same authors of <a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a>, we contacted, unsuccessfully, Dr Connor asking for information about the possible inclusion of some participants in both the studies. </p> <p><a href="./references#CD009683-bbs2-0001" title="Carrasco VargasH , Castellanos RodriguezJ , Aceves RodriguezR . Prospective double blind study of the use of topiramate vs. placebo in the treatment of essential tremor [Estudio prospectivo doble ciego del uso de topiramato vs. placebo en el tratamiento de temblor esencial]. Neurologia, Neurocirugia, Psiquiatria2011;44:1‐5. ">Carrasco Vargas 2011</a> did not provide information on the general and clinical characteristics of the study participants, making homogeneity and comparability of the two groups uncertain. Moreover, the limited follow‐up of only two weeks may have influenced the outcome (efficacy and safety) measurements. For these reasons, the study was judged at high risk of other potential bias. </p> </section> </section> <section id="CD009683-sec-0074"> <h3 class="title" id="CD009683-sec-0074">Effects of interventions</h3> <p>See: <a href="./full#CD009683-tbl-0001"><b>Summary of findings for the main comparison</b> Topiramate for essential tremor</a> </p> <p>See: <a href="./full#CD009683-tbl-0001">summary of findings Table for the main comparison</a> reporting the comparison topiramate versus placebo and GRADE assessment. </p> <p>The studies compared topiramate and placebo, involving a total of 309 participants (159 participants in the topiramate group and 150 participants in the placebo group). </p> <p>We extracted only data from the first treatment phase from <a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a>. These included TRS total score and number of withdrawals. We excluded TRS subscale (A, B and C) scores and number of AEs from the analysis because they were reported only for the second treatment phase. </p> <p>The overall risk of bias was high for all the studies. The quality of evidence in the outcomes ranged from very low to low. </p> <section id="CD009683-sec-0075"> <h4 class="title">Primary outcomes</h4> <section id="CD009683-sec-0076"> <h5 class="title">Functional disability component related to tremor</h5> <p>At the study end (24 weeks), <a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a> reported a mean specific motor tasks/function (TRS subscale B) reduction of 10.3 (SD 12.6) with topiramate and 4.9 (SD 9.5) with placebo (P = 0.001). The MD between the two groups was 5.4 (SD 3.0) (<a href="./references#CD009683-fig-0006" title="">Analysis 1.1</a>; <a href="#CD009683-fig-0004">Figure 4</a>). The mean functional disability (TRS subscale C) reduction reported was 9.4 (SD 13.3) with topiramate and 3.7 (SD 8.8) with placebo (P = 0.001). The MD between the two groups was 5.7 (SD 3.0) (<a href="./references#CD009683-fig-0006" title="">Analysis 1.1</a>). </p> <div class="figure" id="CD009683-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Topiramate versus placebo/open control, outcome: 1.1 Functional disability component related to tremor." data-id="CD009683-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_n/nCD009683-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Topiramate versus placebo/open control, outcome: 1.1 Functional disability component related to tremor. </p> </div> </div> </div> </section> <section id="CD009683-sec-0077"> <h5 class="title">Withdrawal</h5> <p>Two studies reported the number of withdrawals as a primary outcome (<a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a>; <a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a>). Forty‐five participants in the topiramate group and 23 participants in the placebo group withdrew in <a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a>, while 12 participants in the topiramate group and seven participants in placebo group withdrew in <a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a>. We combined data concerning total withdrawals (<a href="./references#CD009683-fig-0007" title="">Analysis 1.2</a>; <a href="#CD009683-fig-0005">Figure 5</a>). There was an increased risk of withdrawals for topiramate, with a Mantel‐Haenszel RR of 1.78 (95% CI 1.23 to 2.60) and a RD of 0.17 (95% CI 0.07 to 0.28). Analysing the causes of study discontinuation, there was evidence to suggest that participants receiving topiramate were more likely to withdraw due to AEs compared to participants receiving placebo, with a Mantel‐Haenszel RR of 3.17 (95% CI 1.79 to 5.63), while there was no evidence of a difference between groups for other reasons for withdrawal (including lack of efficacy, participant choice, lost to follow‐up, non‐compliance and unknown reasons). </p> <div class="figure" id="CD009683-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Topiramate versus placebo/open control, outcome: 1.2 Withdrawals." data-id="CD009683-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_n/nCD009683-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Topiramate versus placebo/open control, outcome: 1.2 Withdrawals. </p> </div> </div> </div> </section> <section id="CD009683-sec-0078"> <h5 class="title">Number of adverse events associated with treatment</h5> <p><a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a> reported the occurrence of AEs, without specifically categorising severity. Overall, 116 participants reported 195 AEs with topiramate, giving a mean of 1.7 AEs per participant. The most frequently reported were: paraesthesia (28 participants), weight loss (22), taste perversion (22), upper respiratory tract infections (19), fatigue (16), nausea (16), appetite decrease (14), memory difficulty (13), dizziness (13), somnolence (12), diarrhoea (12) and headache (11). Participants on placebo treatment reported mainly upper respiratory tract infections (14 participants), dizziness (11), diarrhoea (eight), headache (eight) and nausea (seven), resulting in 71 AEs per 105 participants and a mean of 0.7 AEs per participant. <a href="./references#CD009683-bbs2-0001" title="Carrasco VargasH , Castellanos RodriguezJ , Aceves RodriguezR . Prospective double blind study of the use of topiramate vs. placebo in the treatment of essential tremor [Estudio prospectivo doble ciego del uso de topiramato vs. placebo en el tratamiento de temblor esencial]. Neurologia, Neurocirugia, Psiquiatria2011;44:1‐5. ">Carrasco Vargas 2011</a> reported that two participants treated with topiramate presented with AEs, including nausea and weight loss. There were no AEs in the placebo group. </p> </section> <section id="CD009683-sec-0079"> <h5 class="title">Subgroup analyses</h5> <p>We performed no subgroup analyses of studies categorised according to the combination of anti‐tremor treatments since there were not enough trials or adequate information available. </p> </section> <section id="CD009683-sec-0080"> <h5 class="title">Sensitivity analyses</h5> <p>We performed no sensitivity analyses excluding studies at high risk of bias were due to the small number of trials included in the review and to the absence of trials at low risk of bias. </p> </section> </section> <section id="CD009683-sec-0081"> <h4 class="title">Secondary outcomes</h4> <section id="CD009683-sec-0082"> <h5 class="title">Tremor severity</h5> <p>At the study end (24 weeks), <a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a> reported a mean reduction from baseline of the overall TRS score of 10.8 (SD 9.5) with topiramate and of 5.8 (SD 7.5) with placebo (P &lt; 0.001) and a mean upper‐limb tremor severity reduction of 12.7 (SD 14.8) with topiramate and of 8.9 (SD 13.2) with placebo (P = 0.06). </p> <p><a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a> reported a post‐hoc analysis to assess the potential clinical significance of TRS score change. The authors grouped the participants in categories according to the self‐evaluation scale (very good, good, no change) and calculated the mean TRS score change observed in each category. Based on this analysis, topiramate produced a moderate improvement while placebo produced a mild improvement with unreported statistical and clinical significance. </p> <p>At the end of period one (10 weeks), <a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a> reported a mean overall TRS change from baseline of 8.56 (SD 6.6) with topiramate and of 1.94 (SD 4.7) with placebo (P = 0.0004). </p> <p>At the study end (two weeks), <a href="./references#CD009683-bbs2-0001" title="Carrasco VargasH , Castellanos RodriguezJ , Aceves RodriguezR . Prospective double blind study of the use of topiramate vs. placebo in the treatment of essential tremor [Estudio prospectivo doble ciego del uso de topiramato vs. placebo en el tratamiento de temblor esencial]. Neurologia, Neurocirugia, Psiquiatria2011;44:1‐5. ">Carrasco Vargas 2011</a> reported a mean overall TRS change from baseline of 15.7 (SD 4.5) with topiramate and of 0.2 (SD 1.6) with placebo (P &lt; 0.05). </p> <p>A fixed‐effect meta‐analysis pooled data on efficacy. There was a statistically significant difference in terms of efficacy for TRS total score, which favoured topiramate (MD ‐8.91, 95% CI ‐10.50 to ‐7.33) (<a href="./references#CD009683-fig-0006" title="">Analysis 1.1</a>; <a href="#CD009683-fig-0004">Figure 4</a>). </p> <p>Scores of a non‐validated participant self‐evaluation rating scale and of an investigator‐rated global assessment scale were reported in <a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a>. The participant‐rated global assessment indicated that 69% of participants in the topiramate group and 15% of participants in the placebo group reported a "good" or "very good" improvement; similarly, investigators attributed a "good" or "very good" improvement to 67% of participants in the topiramate group and to 20% of participants in the placebo group. </p> </section> <section id="CD009683-sec-0083"> <h5 class="title">Quality of life</h5> <p>None of the studies reported QoL.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009683-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009683-sec-0084"></div> <section id="CD009683-sec-0085"> <h3 class="title" id="CD009683-sec-0085">Summary of main results</h3> <p>The review included three RCTs comparing topiramate with placebo for the treatment of ET (<a href="./references#CD009683-bbs2-0001" title="Carrasco VargasH , Castellanos RodriguezJ , Aceves RodriguezR . Prospective double blind study of the use of topiramate vs. placebo in the treatment of essential tremor [Estudio prospectivo doble ciego del uso de topiramato vs. placebo en el tratamiento de temblor esencial]. Neurologia, Neurocirugia, Psiquiatria2011;44:1‐5. ">Carrasco Vargas 2011</a>; <a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a>; <a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a>; ). The studies involved a population of 309 participants presenting with moderate to severe ET, mostly of long duration (about 20 years). One study assessed treatment efficacy in terms of function and ability improvement, showing a statistically significant difference favouring topiramate versus placebo (<a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a>). However, the quality of the evidence in this outcome was very low. However, there was an almost two‐fold risk of study withdrawal, mainly due to the occurrence of AEs, for participants treated with topiramate. The quality of the evidence for these outcomes was low. Thus, these effect estimates should be interpreted cautiously due to the scarce number of trials included, the high risk of bias and the low to very low quality of evidence provided. </p> </section> <section id="CD009683-sec-0086"> <h3 class="title" id="CD009683-sec-0086">Overall completeness and applicability of evidence</h3> <p>In this review, efficacy outcomes were measured with the TRS scale. Only one study adequately assessed one of the primary outcomes (functional disability component related to tremor), which was measured as a reduction of the TRS subscales B and C scores (<a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a>). Given the lack of studies reporting what TRS score differences should be considered clinically relevant, the definition of improvement was taken from the original articles. <a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a> assessed the potential clinical significance of TRS score changes in a post‐hoc analysis. However, we believe the definition of improvement provided was inadequate because it was based on a retrospective assessment of the level of improvement, because it included only the TRS total score disregarding the TRS subscales scores, it contained an overlap in attributing the class of improvement (the number 10 was included in two consecutive categories) and it was tailored on an unvalidated global assessment scale (completed by both participants and raters), without specifying if the analysis was based on participant‐rated or on investigator‐rated scores. <a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a> and <a href="./references#CD009683-bbs2-0001" title="Carrasco VargasH , Castellanos RodriguezJ , Aceves RodriguezR . Prospective double blind study of the use of topiramate vs. placebo in the treatment of essential tremor [Estudio prospectivo doble ciego del uso de topiramato vs. placebo en el tratamiento de temblor esencial]. Neurologia, Neurocirugia, Psiquiatria2011;44:1‐5. ">Carrasco Vargas 2011</a> did not report TRS subscale B and C scores, or provide a definition of improvement, making the interpretation of the results difficult from a clinical perspective. </p> <p>Despite being considered a recommended scale in the assessment of tremor severity (<a href="./references#CD009683-bbs2-0020" title="ElbleR , BainP , ForjazMJ , HaubenbergerD , TestaC , GoetzCG , et al. Task Force Report: scales for screening and evaluating tremor. Critique and recommendations. Movement Disorders2013;28(13):1793‐800. ">Elble 2013</a>), the TRS scale has demonstrated limited inter‐rater reliability, unless the raters have been rigorously trained (<a href="./references#CD009683-bbs2-0052" title="StacyMA , ElbleRJ , OndoWG , WuSC , HulihanJ , for the TRS Study Group. Assessment of interrater and intrarater reliability of the Fahn‐Tolosa‐Marin Tremor Rating Scale in essential tremor. Movement disorders2007;22:833‐8. ">Stacy 2007</a>). This could influence results and should be taken into account especially in multicentre trials. Moreover, since TRS sensitivity in detecting relevant clinical changes in studies assessing ET therapies has not been evaluated, the clinical relevance of statistically significant changes in TRS scores is unclear. </p> <p>The number of AEs was not adequately reported in <a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a> and <a href="./references#CD009683-bbs2-0001" title="Carrasco VargasH , Castellanos RodriguezJ , Aceves RodriguezR . Prospective double blind study of the use of topiramate vs. placebo in the treatment of essential tremor [Estudio prospectivo doble ciego del uso de topiramato vs. placebo en el tratamiento de temblor esencial]. Neurologia, Neurocirugia, Psiquiatria2011;44:1‐5. ">Carrasco Vargas 2011</a> and it was not measured using standardised questionnaires in <a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a>. Unreported symptoms could have been neglected. It should be also underlined that the risk of AEs could have been further underestimated due to the exclusion of people with previously reported AEs or hypersensitivity to topiramate. </p> <p>An additional remark regarding topiramate therapeutic scheme should be made. Given the lack of studies assessing the minimum efficacious dose of topiramate for the treatment of ET, the dose used in these trials (ranging between 25 mg/day and 400 mg/day) was arbitrarily chosen and thus, could have been inadequate (excessive or insufficient), as well as the duration of the follow‐up. </p> <p>Finally, the effects of treatment on participants' functional ability, QoL and validated participant self‐evaluating rating scales were not reported, representing a limitation in the overall completeness of the assessment and the ability to balance the overall risk‐benefit ratio linked to treatment. </p> </section> <section id="CD009683-sec-0087"> <h3 class="title" id="CD009683-sec-0087">Quality of the evidence</h3> <p>Review of bias evaluation and strength of evidence assessment disclosed several major limitations in the evidence‐base. Several important factors limited the validity of the reported results: </p> <p> <ul id="CD009683-list-0015"> <li> <p>the treatment effect was measured using a carried forward procedure to deal with a significant amount of missing outcome data; </p> </li> <li> <p>there was a high risk of attrition bias given the number of withdrawals due to AEs, especially among participants treated with topiramate; </p> </li> <li> <p>the presence of a large proportion of participants receiving other anti‐tremor medications during the study period (50% in <a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a> and 89% in <a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a>) might have influence the efficacy measures; </p> </li> <li> <p>there were potential conflicts of interest due to the presence of authors sponsored by or affiliated to the pharmaceutical company of topiramate. </p> </li> </ul> </p> <p>Different major points seriously limited the global quality of the evidence produced by these studies. </p> <p>Blinding of outcome assessment was described in two studies (<a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a>; <a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a>) and not reported in one (<a href="./references#CD009683-bbs2-0001" title="Carrasco VargasH , Castellanos RodriguezJ , Aceves RodriguezR . Prospective double blind study of the use of topiramate vs. placebo in the treatment of essential tremor [Estudio prospectivo doble ciego del uso de topiramato vs. placebo en el tratamiento de temblor esencial]. Neurologia, Neurocirugia, Psiquiatria2011;44:1‐5. ">Carrasco Vargas 2011</a>); however, even in the first, the well documented AEs of topiramate make it likely that treated participants had become aware of the treatment they were receiving during the course of the trial, and these trials should be regarded as single‐blind. </p> <p>In addition to this, the assessment of the quality of the evidence highlighted the presence of potential indirectness related to the uncertain relevance of the reported TRS‐score changes as indicators of a clinical improvement (which is meaningful to people with ET), and the presence of imprecision of the evidence due to the small sample size and small number of included studies. </p> </section> <section id="CD009683-sec-0088"> <h3 class="title" id="CD009683-sec-0088">Potential biases in the review process</h3> <p>To identify all relevant studies minimising the risk of bias, we performed a comprehensive systematic review, searching different databases without language restrictions. In addition to all the limitations previously highlighted, there are a number of other potential biases. First, we included a trial reporting pooled data. Additional information from authors and the original reports were not available, making it impossible to clarify the method used to combine data and to exclude the possibility that some participants were included in both trials. Furthermore, since people undergoing additional anti‐tremor therapies were not separately assessed in the original studies, a potential combined effect of different treatments was included in the results presented. </p> </section> <section id="CD009683-sec-0089"> <h3 class="title" id="CD009683-sec-0089">Agreements and disagreements with other studies or reviews</h3> <p>There are two major reviews of the literature analysing topiramate treatment for ET (<a href="./references#CD009683-bbs2-0060" title="ZappiaM , AlbaneseA , BrunoE , ColosimoC , FilippiniG , MartinelliP , et al. Italian Movement Disorders Association (DISMOV‐SIN) Essential Tremor Committee. Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. Journal of Neurology2013;260(3):714‐40. ">Zappia 2013</a>; <a href="./references#CD009683-bbs2-0062" title="ZesiewiczTA , ElbleR , LouisED , HauserRA , SullivanKL , DeweyRBJr , et al. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology2005;64(12):2008‐20. ">Zesiewicz 2005</a>). These reviews produced different conclusions compared to the present work, due to the use of different methodology and criteria for rating the quality of the studies and of the evidence. </p> <p> <ul id="CD009683-list-0016"> <li> <p>The Practice Parameter for Essential Tremor concluded that topiramate should be used as second‐line therapy (<a href="./references#CD009683-bbs2-0062" title="ZesiewiczTA , ElbleR , LouisED , HauserRA , SullivanKL , DeweyRBJr , et al. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology2005;64(12):2008‐20. ">Zesiewicz 2005</a>). The review was developed on a four‐tiered classification scheme based mainly on study design and including uncontrolled studies, case series and case reports. Neurophysiological parameters (electromyographic recordings, accelerometry, spirography, digitising tablets) were considered among outcome measures. Recommendation on topiramate were formulated on the basis of three class II studies (<a href="./references#CD009683-bbs2-0017" title="ConnorGS . A double‐blind placebo‐controlled trial of topiramate treatment for essential tremor. Neurology2002;59(1):132‐4. ">Connor 2002</a>; <a href="./references#CD009683-bbs2-0029" title="HulihanJ , ConnorGS , Shu‐ChenW . Topiramate in essential tremor: pooled data from a double‐blind, placebo‐controlled, crossover trial. American Academy of Neurology2003;Abstracts:P04.068. ">Hulihan 2003</a>; <a href="./references#CD009683-bbs2-0042" title="OndoWG , JankovicJ , StacyMA . Topiramate for essential tremor. Neurology2004;62:LBS.004. ">Ondo 2004</a>) and one class IV study (<a href="./references#CD009683-bbs2-0006" title="Gálvez‐JiménezN , HargreaveM . Topiramate and essential tremor. Annals of Neurology2000;47(6):837‐8. ">Gálvez‐Jimenez 2000</a>). </p> </li> <li> <p>The systematic review of evidence and recommendations from the Italian Movement Disorders Association (DISMOV‐SIN) considered the potential role of topiramate among first‐line treatments (<a href="./references#CD009683-bbs2-0060" title="ZappiaM , AlbaneseA , BrunoE , ColosimoC , FilippiniG , MartinelliP , et al. Italian Movement Disorders Association (DISMOV‐SIN) Essential Tremor Committee. Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. Journal of Neurology2013;260(3):714‐40. ">Zappia 2013</a>). The review used GRADE to assign the level of evidence. Besides RCTs, the review also included case series, case reports and studies using neurophysiological assessment of tremor. The conclusions on topiramate were based on the analysis of five studies that were assigned a higher quality category compared to studies investigating propranolol and primidone, classically considered as first‐line therapy (<a href="./references#CD009683-bbs2-0002" title="ConnorGS , EdwardsK , TarsyD . Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology2008;31(2):97‐103. ">Connor 2008</a>; <a href="./references#CD009683-bbs2-0005" title="FrimaN , GrünewaldRA . A double‐blind, placebo‐controlled, crossover trial of topiramate in essential tremor. Clinical Neuropharmacology2006;29(2):94‐6. ">Frima 2006</a>; <a href="./references#CD009683-bbs2-0006" title="Gálvez‐JiménezN , HargreaveM . Topiramate and essential tremor. Annals of Neurology2000;47(6):837‐8. ">Gálvez‐Jimenez 2000</a>; <a href="./references#CD009683-bbs2-0007" title="GattoEM , RocaMC , RainaG , MicheliF . Low doses of topiramate are effective in essential tremor: a report of three cases. Clinical Neuropharmacology2003;26(6):294‐6. ">Gatto 2003</a>; <a href="./references#CD009683-bbs2-0003" title="OndoWG , JankovicJ , ConnorJS , PahwaR , ElbleR , StacyMA , Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology2006;66:672‐7. ">Ondo 2006</a>). </p> </li> </ul> </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009683-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/urn:x-wiley:14651858:media:CD009683:CD009683-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_t/tCD009683-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009683-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_n/nCD009683-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/full#CD009683-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_n/nCD009683-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009683-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/urn:x-wiley:14651858:media:CD009683:CD009683-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_t/tCD009683-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009683-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_n/nCD009683-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/full#CD009683-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_n/nCD009683-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009683-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/urn:x-wiley:14651858:media:CD009683:CD009683-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_t/tCD009683-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009683-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_n/nCD009683-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/full#CD009683-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_n/nCD009683-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009683-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/urn:x-wiley:14651858:media:CD009683:CD009683-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_t/tCD009683-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Topiramate versus placebo/open control, outcome: 1.1 Functional disability component related to tremor." data-id="CD009683-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_n/nCD009683-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Topiramate versus placebo/open control, outcome: 1.1 Functional disability component related to tremor. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/full#CD009683-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_n/nCD009683-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009683-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/urn:x-wiley:14651858:media:CD009683:CD009683-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_t/tCD009683-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Topiramate versus placebo/open control, outcome: 1.2 Withdrawals." data-id="CD009683-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_n/nCD009683-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Topiramate versus placebo/open control, outcome: 1.2 Withdrawals. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/full#CD009683-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_n/nCD009683-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009683-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/urn:x-wiley:14651858:media:CD009683:CD009683-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_t/tCD009683-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topiramate versus placebo/open control, Outcome 1 Functional disability component related to tremor." data-id="CD009683-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_n/nCD009683-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Topiramate versus placebo/open control, Outcome 1 Functional disability component related to tremor. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/references#CD009683-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_n/nCD009683-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009683-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/urn:x-wiley:14651858:media:CD009683:CD009683-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_t/tCD009683-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topiramate versus placebo/open control, Outcome 2 Withdrawals." data-id="CD009683-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_n/nCD009683-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Topiramate versus placebo/open control, Outcome 2 Withdrawals.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/references#CD009683-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/media/CDSR/CD009683/image_n/nCD009683-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009683-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Topiramate for essential tremor</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Topiramate for essential tremor</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with essential tremor </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> topiramate </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Topiramate</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Functional disability</b> </p> <p><b>(follow‐up duration 24 weeks)</b> </p> <p>TRS subscale B score (motor tasks)</p> <p>TRS subscale C score (functional disability)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in the control group was<br/> <b>4.9 points</b> for TRS subscale B and <b>3.7 points</b> for TRS subscale C. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in the intervention groups was<br/> <b>5.4 (2.38 to 8.42) points greater</b> for TRS subscale B and <b>5.7 (2.66 to 8.74) points greater</b> for TRS subscale C. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>223<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Study withdrawal</b> </p> <p><b>(follow‐up duration 10 to 24 weeks)</b> </p> <p>Number of participants withdrawn from the study</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.78</b> <br/> (1.23 to 2.60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>285<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>217 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>347 per 1000</b> <br/> (252 to 458) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events</b> </p> <p><b>(follow‐up duration 24 weeks)</b> </p> <p>Number of AEs</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>221<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 AEs per 105 participants</b> <br/> (mean 0.7 AEs reported by each participant) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>195 AEs per 116 participants</b> <br/> (mean of 1.7 AEs reported by each participant) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>AE:</b> adverse event; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>TRS:</b> Tremor Rating Scale. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded due to serious risk of bias: high number of study withdrawals (attrition bias); blinding of outcome assessment probably revealed by the presence of serious AEs in the topiramate group: trials should be regarded as single blind (detection bias); potential conflicts of interest due to the presence of authors sponsored by pharmaceutical companies.<br/> <sup>2</sup> Downgraded due to serious indirectness: uncertainty about the relevance of the reported TRS‐score changes as indicators of important clinical improvement. </p> <p><sup>3</sup> Downgraded due to imprecision: small sample size (&lt; 300 participants) and small number of included studies (three). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Topiramate for essential tremor</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/full#CD009683-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009683-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topiramate versus placebo/open control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Functional disability component related to tremor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Change in TRS subscale B score </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.4 [‐8.42, ‐2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Change in TRS subscale C score </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.7 [‐8.74, ‐2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Change in TRS total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.91 [‐10.50, ‐7.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Withdrawals <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Withdrawals: lack of efficacy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.02, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Withdrawals: AEs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.17 [1.79, 5.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Withdrawals: other reasons</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.45, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Withdrawals: total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [1.23, 2.60]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topiramate versus placebo/open control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009683.pub2/references#CD009683-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009683.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009683-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009683-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009683-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="pl#CD009683-note-0003">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD009683-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009683-note-0008">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009683\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009683\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009683\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009683\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009683\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009683\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009683\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009683\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009683\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009683\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009683\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009683\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009683\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009683\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009683\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009683\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009683\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009683\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009683.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009683.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009683.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009683.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009683.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728613401"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009683.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728613405"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009683.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec8c16a46f431',t:'MTc0MDcyODYxMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 